CIK 0001854270 · <br>Emerging growth company
Senti Biosciences Holdings, Inc.
Sign in to watch- Ticker
- SNTI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 862437900
- Phone
- (650) 239-2030
- Business address
- 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Senti Biosciences, Inc., Senti Biosciences, Inc.\, Dynamics Special Purpose Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-21 | Rajangam Kanya Pres. & Chief Med. & Dev. Off. | Shares withheld for taxes | −19,953 | 54,890 | ||
| 2026-10-21 | Lu Timothy K CEO | Shares withheld for taxes | −157,312 | 482,271 | ||
| 2026-03-09 | Rajangam Kanya Pres. & Chief Med. & Dev. Off. | Shares withheld for taxes | −10,757 | 74,843 | ||
| 2026-03-09 | Lu Timothy K CEO | Shares withheld for taxes | −80,666 | 639,583 | ||
| 2026-02-02 | Rajangam Kanya Pres. & Chief Med. & Dev. Off. | Shares withheld for taxes | −1,384 | 85,600 | ||
| 2026-02-02 | Lu Timothy K CEO | Shares withheld for taxes | −4,191 | 720,249 | ||
| 2025-07-18 | Baum Bryan Daniel Director | Grant or award · Stock Option (Right to Buy) | +43,900 | 43,900 | ||
| 2025-06-25 | Collins James J. Director | Grant or award · Stock Option (Right to Buy) | +21,950 | 21,950 | ||
| 2025-06-25 | Hsiung Feng Director | Grant or award · Stock Option (Right to Buy) | +21,950 | 21,950 | ||
| 2025-06-25 | Schulz Fran Director | Grant or award · Stock Option (Right to Buy) | +21,950 | 21,950 | ||
| 2025-06-25 | COOPERSTONE BRENDA Director | Grant or award · Stock Option (Right to Buy) | +21,950 | 21,950 | ||
| 2025-06-25 | Tang Donald F Director | Grant or award · Stock Option (Right to Buy) | +21,950 | 21,950 | ||
| 2025-06-25 | Mathers Edward T Director | Grant or award · Stock Option (Right to Buy) | +21,950 | 21,950 | ||
| 2025-03-10 | Celadon Partners SPV 24 10% owner | Conversion | +9,777,000 | 9,777,000 | ||
| 2025-03-10 | Celadon Partners SPV 24 10% owner | Conversion · Series A Convertible Preferred Stock | −9,777 | 0 | ||
| 2025-03-10 | BAYER HEALTHCARE LLC 10% owner | Conversion | +2,222,000 | 2,809,848 | ||
| 2025-03-10 | BAYER HEALTHCARE LLC 10% owner | Conversion · Series A Convertible Preferred Stock | −2,222 | 0 | ||
| 2025-03-10 | New Enterprise Associates 15, L.P. 10% owner | Conversion | +3,333,000 | 3,775,615 | ||
| 2025-03-10 | New Enterprise Associates 15, L.P. 10% owner | Conversion · Series A Convertible Preferred Stock | −3,333 | 0 | ||
| 2025-03-10 | Rajangam Kanya Pres. & Chief Med. & Dev. Off. | Conversion | +33,000 | $2.25 | $74K | 33,000 |
Page 1 of 4 · 79 trades